National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Thyroid Cancer Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 06/04/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Stage I and II Papillary and Follicular Thyroid Cancer






Stage III Papillary and Follicular Thyroid Cancer






Stage IV Papillary and Follicular Thyroid Cancer






Medullary Thyroid Cancer






Anaplastic Thyroid Cancer






Recurrent Thyroid Cancer






Get More Information From NCI






Changes to This Summary (06/04/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Stage IV Papillary and Follicular Thyroid Cancer

Current Clinical Trials

The most common sites of metastases are lymph nodes, lung, and bone. Treatment of lymph node metastases alone is often curative. Treatment of distant metastases is usually not curative but may produce significant palliation.

Standard treatment options:

  1. I131: Metastases that demonstrate uptake of this isotope may be ablated by therapeutic doses of I131.


  2. External-beam radiation therapy for patients with localized lesions that are unresponsive to I131.[1]


  3. Resection of limited metastases, especially symptomatic metastases, should be considered when the tumor has no uptake of I131.


  4. Thyroid-stimulating hormone suppression with thyroxine is also effective in many lesions not sensitive to I131.


Patients unresponsive to I131 should also be considered candidates for clinical trials testing new approaches to this disease.

Treatment options under clinical evaluation:

  • Clinical trials evaluating new treatment approaches to this disease should also be considered for these patients. Chemotherapy has been reported to produce occasional complete responses of long duration.[2-4]
Current Clinical Trials

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage IV papillary thyroid cancer and stage IV follicular thyroid cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site.

References

  1. Simpson WJ, Carruthers JS: The role of external radiation in the management of papillary and follicular thyroid cancer. Am J Surg 136 (4): 457-60, 1978.  [PUBMED Abstract]

  2. Gottlieb JA, Hill CS Jr, Ibanez ML, et al.: Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. Cancer 30 (3): 848-53, 1972.  [PUBMED Abstract]

  3. Harada T, Nishikawa Y, Suzuki T, et al.: Bleomycin treatment for cancer of the thyroid. Am J Surg 122 (1): 53-7, 1971.  [PUBMED Abstract]

  4. Shimaoka K, Schoenfeld DA, DeWys WD, et al.: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 (9): 2155-60, 1985.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov